Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2011-07-12
2011-07-12
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S489000
Reexamination Certificate
active
07976847
ABSTRACT:
The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.
REFERENCES:
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4272398 (1981-06-01), Jaffe
patent: 4627839 (1986-12-01), Young
patent: 4720483 (1988-01-01), Jansz et al.
patent: 4764378 (1988-08-01), Keith et al.
patent: 4797285 (1989-01-01), Barenholz et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4957119 (1990-09-01), de Nijs
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5088505 (1992-02-01), De Nijs
patent: 5126134 (1992-06-01), Heim et al.
patent: 5190761 (1993-03-01), Liburdy
patent: 5271961 (1993-12-01), Mathiowitz et al.
patent: 5324519 (1994-06-01), Dunn et al.
patent: 5336489 (1994-08-01), Strom
patent: 5637309 (1997-06-01), Tajima et al.
patent: 5702716 (1997-12-01), Dunn et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5744153 (1998-04-01), Yewey et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5863554 (1999-01-01), Illum
patent: 5910482 (1999-06-01), Yallampalli et al.
patent: 5958877 (1999-09-01), Wimalawansa
patent: 5985305 (1999-11-01), Peery et al.
patent: 5990194 (1999-11-01), Dunn et al.
patent: 6143314 (2000-11-01), Chandrashekar et al.
patent: 6201072 (2001-03-01), Rathi et al.
patent: 6306406 (2001-10-01), Deluca
patent: 6358247 (2002-03-01), Altman et al.
patent: 6403114 (2002-06-01), Rickey et al.
patent: RE37950 (2002-12-01), Dunn et al.
patent: 6503534 (2003-01-01), Pellet et al.
patent: 6525102 (2003-02-01), Chen et al.
patent: 6528080 (2003-03-01), Dunn et al.
patent: 6544252 (2003-04-01), Theeuwes et al.
patent: 6555156 (2003-04-01), Loughman
patent: 6565874 (2003-05-01), Dunn et al.
patent: 6582080 (2003-06-01), Gibbon et al.
patent: 6589549 (2003-07-01), Shih et al.
patent: 6809079 (2004-10-01), Southard et al.
patent: 2008/0097503 (2008-04-01), Creaven
patent: 2009/0023643 (2009-01-01), Southard et al.
patent: 2009/0023644 (2009-01-01), Southard et al.
patent: 0 467 389 (1992-01-01), None
patent: 0 467 389 (1992-01-01), None
patent: 0 539 751 (1993-05-01), None
patent: 0 539 751 (1993-05-01), None
patent: 0 645 136 (1995-03-01), None
patent: 0 645 136 (1995-03-01), None
patent: 0 765 659 (1997-04-01), None
patent: 0 845 269 (1998-06-01), None
patent: 0 845 269 (1998-06-01), None
patent: 4-503163 (1992-06-01), None
patent: 5-103838 (1993-04-01), None
patent: 5-305135 (1993-11-01), None
patent: 7-89876 (1995-04-01), None
patent: 9-511741 (1997-11-01), None
patent: 2002-501908 (2002-01-01), None
patent: 2002-516910 (2002-06-01), None
patent: 2002-528403 (2002-09-01), None
patent: 2003-104913 (2003-04-01), None
patent: WO-90/03768 (1990-04-01), None
patent: WO-93/23011 (1993-11-01), None
patent: WO-95/27481 (1995-10-01), None
patent: WO-96/30013 (1996-10-01), None
patent: WO-99/18142 (1999-04-01), None
patent: WO-99/38536 (1999-08-01), None
patent: WO-00/24374 (2000-05-01), None
patent: WO-02/098446 (2002-12-01), None
patent: WO-03/059250 (2003-07-01), None
patent: WO-03/059250 (2003-07-01), None
patent: WO-03/063799 (2003-08-01), None
patent: WO-03/063799 (2003-08-01), None
patent: WO-03/013538 (2003-12-01), None
patent: WO-2005/067890 (2005-07-01), None
patent: WO-2005/067890 (2005-07-01), None
patent: WO-2005/070444 (2005-08-01), None
patent: WO-2005/070444 (2005-08-01), None
patent: WO-2005/070444 (2005-08-01), None
patent: WO-2005/070445 (2005-08-01), None
patent: WO-2005/070445 (2005-08-01), None
patent: WO-2006/029320 (2006-03-01), None
Asahina, A. et al. (Aug. 1995). “Specific Induction of cAMP in Langerhans Cells by Calcitonin Gene-Related Peptide: Relevance to Functional Effects,”PNAS USA92:8323-8327.
Brindis, R.G. et al. (Jun. 15, 2001). “The American College of Cardiology-National Cardiovascular Data Registry™ (ACC-NCDR™): Building a National Clinical Data Repository,”Journal of the American College of Cardiology37(8):2240-2245.
Chai, W. et al. (Feb. 15, 2006, e-pub. Jan. 24, 2006). “The Role of Calcitonin Gene-Related Peptide (CGRP) in Ischemic Preconditioning in Isolated Red Hearts,” European Journal of Pharmacology 531 (1-3):246-253.
Duzendorfer, S. et al. (2002-2003). “Neuropeptide-Induced Inhibition of IL-16 Release from Eosinophils,”NeuroImmunoModulation10:217-223.
Feng, Y. et al. (1997). “Inhibition of LPS-Induced TNF-α Production by Calcitonin Gene-Related Peptide (CGR) in Cultured Mouse Peritoneal Macrophages,”Life Sciences61(20):PL-281-PL-287.
Fernandez, S. et al. (May 2000). “Calcitonin-Gene Related Peptide (CGRP) Inhibits Interleukin-7-Induced Pre-B Cell Colony Formation,”Journal of Leukocyte Biology67:669-676.
Foncea, R. et al. (Aug. 1, 1997). “Insulin-Like Growth Factor-I Rapidly Activates Multiple Signal Transduction Pathways in Cultured Rat Cardiac Myocytes,”J. Biol. Chem.272(31):19115-19124.
GenBank Accession No. 1005250A, last updated May 8, 1996, located at <http://www.ncbi.nlm.nih.gov/protein/223948?report=genpept>, last visited on Apr. 28, 2009, 2 pages.
International Search Report mailed on Jul. 5, 2006, for PCT Application No. PCT/US2005/001230, filed on Jan. 13, 2005, two pages.
International Search Report mailed on Oct. 5, 2006, for PCT Application No. PCT/US2005/001224, filed on Jan. 13, 2005, five pages.
Morris, H.R. et al. (Apr. 1984). “Isolation and Characterization of Human Calcitonin Gene-Related Peptide,”Nature308:746-748.
Nishikimi, T. et al. (Jul. 24, 1998). “Effect of Adrenomedullin on cAMP and cGMP Levels in Rat Cardiac Myocytes and Nonmyocytes,”Eur. J. Pharmacol.353(2/3):337-344.
Scanlon, P.J. et al. (1999). “ACC/AGA Guidelines for Coronary Angiography: A Report of The American College of Cardiology/American Heart Association Task Force on Practice Guidelines, (Committee on Coronary Angiography)”The Journal of the American College of Cardiology33(6):1756-17824.
Torii, H. et al. (Feb. 1997). “Regulation of Cytokine Expression in Macrophages and the Langerhans Cell-Like Line XS52 by Calcitonin Gene-Related Peptide,”Leukoc. Biol.61:216-223.
Wolfrum, S. et al. (Apr. 15, 2005). “Calcitonin Gene Related Peptide Mediates Cardioprotection by Remote Preconditioning,”Regulatory Peptides127 (1-3):217-224.
Written Opinion mailed on Jul. 5, 2006, for PCT Application No. PCT/US2005/001230, filed on Jan. 13, 2005, nine pages.
Written Opinion mailed on Oct. 5, 2006, for PCT Application No. PCT/US2005/001224, filed on Jan. 13, 2005, seven pages.
Anand, I.S. at al. (Jan. 1991). “Cardiovascular and Hormonal Effects of Calcitonin Gene-Related Peptide in Congestive Heart Failure,”J. Am. Coll. Cardiol. 17(1):208-217.
Anonymous (May 1990).The FASEB Journal4(8):2544.
Benita, S. et al. (Dec. 1984). “Characterization of Drug-Loaded poly(d,l-lactide) Microspheres,”Journal of Pharmaceutical Sciences73(12):1721-1724.
Fleisher, D. et al. (May 22, 1996). “Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs,”Advanced Drug Delivery Reviews19(2):115-130.
Gennari, C. et al. (Mar. 1990). “Improved Cardiac Performance with Human Calcitonin Gene Related Peptide in Patients with Congestive Heart Failure,”Cardiovascular Res.24(3):239-241.
Haegerstrand, A. et al. (May 1990). “Calcitonin Gene-Related Peptide Stimulates Proliferation of Human Endothelial Cells,”Proc. Natl. Acad. Sci. USA87(9):3299-3303.
Hunt, S.A. et al. (2001).ACC/AHA Practice Guidelines: ACC/AHA Guid
Southard George L.
Southard Jeffrey L.
Li Ruixiang
Schwegman Lundberg & Woessner, P.A.
VasoGenix Pharmaceuticals, Inc.
LandOfFree
Controlled release CGRP delivery composition for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release CGRP delivery composition for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release CGRP delivery composition for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2655195